0.50
前日終値:
$0.5175
開ける:
$0.518
24時間の取引高:
154.42K
Relative Volume:
0.89
時価総額:
$47.87M
収益:
$1.29M
当期純損益:
$-29.87M
株価収益率:
-1.3889
EPS:
-0.36
ネットキャッシュフロー:
$-14.70M
1週間 パフォーマンス:
+5.26%
1か月 パフォーマンス:
+1.21%
6か月 パフォーマンス:
-27.92%
1年 パフォーマンス:
-38.26%
VolitionRX Ltd Stock (VNRX) Company Profile
名前
VolitionRX Ltd
セクター
電話
646 650 1351
住所
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
VNRX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
VNRX
VolitionRX Ltd
|
0.50 | 47.87M | 1.29M | -29.87M | -14.70M | -0.36 |
![]()
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-08 | 開始されました | H.C. Wainwright | Buy |
2023-02-01 | ダウングレード | The Benchmark Company | Buy → Hold |
2022-02-17 | 再開されました | Cantor Fitzgerald | Overweight |
2021-03-10 | 開始されました | Cantor Fitzgerald | Overweight |
2018-05-16 | 開始されました | Maxim Group | Buy |
2018-05-14 | 繰り返されました | The Benchmark Company | Buy |
2016-09-07 | 繰り返されました | Rodman & Renshaw | Buy |
2016-02-01 | 開始されました | Rodman & Renshaw | Buy |
すべてを表示
VolitionRX Ltd (VNRX) 最新ニュース
VolitionRx (VNRX) Expected to Announce Quarterly Earnings on Monday - Defense World
VolitionRx Updates Progress Of Nu.Q NETs Test Adoption - marketscreener.com
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World
VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
VolitionRx enters new sales agreement, terminates old one - Investing.com Australia
VolitionRx enters new sales agreement, terminates old one By Investing.com - Investing.com South Africa
VolitionRX Ltd (AMEX: VNRX): An Enticing Stock To Watch - stocksregister.com
Insider Buying: Reynolds Cameron John, VolitionRX Ltd [VNRX] President and CEO invested 181,818 shares - knoxdaily.com
VolitionRx (NYSE:VNRX) Now Covered by StockNews.com - The AM Reporter
H.C. Wainwright maintains buy on VolitionRX with $2.50 target By Investing.com - Investing.com South Africa
VolitionRx (NYSE:VNRX) Coverage Initiated at HC Wainwright - The AM Reporter
What is HC Wainwright’s Estimate for VolitionRx Q1 Earnings? - Defense World
VolitionRX stock holds as Benchmark maintains rating - Investing.com Australia
VolitionRx (NYSE:VNRX) Now Covered by Analysts at HC Wainwright - Defense World
VolitionRX stock holds as Benchmark maintains rating By Investing.com - Investing.com South Africa
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
HC Wainwright Initiates VolitionRx With Buy Rating, $2.50 Price Target - marketscreener.com
VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
VolitionRx Moves to Register Warrant Shares on New Form By Investing.com - Investing.com South Africa
VolitionRx Moves to Register Warrant Shares on New Form - Investing.com
VolitionRx Limited (AMEX:VNRX) Q4 2024 Earnings Call Transcript - Insider Monkey
VolitionRx Ltd. Earnings Call Highlights Growth and Challenges - TipRanks
VolitionRX Ltd (VNRX) Reports Q4 EPS of -0.06, Revenue Surges to $1.2 Million, Exceeding Estimates - GuruFocus
VolitionRx (VNRX) Sees Strong Growth with Doubling of Nu.Q Vet T - GuruFocus
Earnings call transcript: VolitionRx revenue beats forecast in Q4 2024 - Investing.com India
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances - Yahoo Finance
VolitionRx Limited Reports Strong 2024 Financial Results - TipRanks
Volitionrx Ltd earnings missed, revenue fell short of estimates - Investing.com
Volitionrx Ltd earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Earnings call transcript: VolitionRx revenue beats forecast in Q4 2024 By Investing.com - Investing.com UK
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update - Financial Times
A Look Ahead: VolitionRX's Earnings Forecast - Benzinga
Volition Announces Two Poster Presentations At Esmo's European Lung Cancer Congress 2025 - MarketScreener
Volitionrx director Innes buys $99,999 in common stock By Investing.com - Investing.com Canada
VolitionRx CEO Cameron Reynolds acquires $99,999 in stock - Investing.com
Volitionrx director Innes buys $99,999 in common stock - Investing.com
VolitionRx CEO Cameron Reynolds acquires $99,999 in stock By Investing.com - Investing.com UK
VolitionRx secures up to $2.3 million in direct offering By Investing.com - Investing.com South Africa
VolitionRx secures up to $2.3 million in direct offering - Investing.com India
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering - Marketscreener.com
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update - Yahoo Finance
D. Boral Capital Reaffirms “Buy” Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRX Reports Positive Results of Automated Nu.Q Cancer Immunoassay Test in Development - Marketscreener.com
VolitionRx reports results from Nu.Q Cancer test - TipRanks
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry - Yahoo Finance
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer - Yahoo Finance
Volitionrx announces pricing of public offering of 3.77 mln shares - Reuters
Volition Proudly Sponsors the 44th ISICEM Congress - Yahoo Finance
VolitionRx (VNRX) Projected to Post Quarterly Earnings on Monday - Defense World
VolitionRX Ltd (VNRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):